Corbus Pharmaceuticals Holdings, Inc.
CRBP
$10.03
$0.141.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -2.91% | 78.01% | |||
| Gross Profit | 2.91% | -78.01% | |||
| SG&A Expenses | -4.06% | 8.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.64% | 48.03% | |||
| Operating Income | -2.64% | -48.03% | |||
| Income Before Tax | -4.03% | -78.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.03% | -78.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.03% | -78.15% | |||
| EBIT | -2.64% | -48.03% | |||
| EBITDA | -2.80% | -48.97% | |||
| EPS Basic | -3.70% | -77.81% | |||
| Normalized Basic EPS | -3.70% | -77.83% | |||
| EPS Diluted | -3.70% | -77.81% | |||
| Normalized Diluted EPS | -3.70% | -77.83% | |||
| Average Basic Shares Outstanding | 0.31% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.31% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||